Can a heart drug ease long COVID symptoms?

NCT ID NCT06305806

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested whether ivabradine, a drug that slows heart rate, can reduce symptoms like dizziness and rapid heartbeat in people with long COVID. 181 participants received either ivabradine or a placebo for 3 months, with follow-up for another 3 months. The study measured changes in symptom scores and daily activity interference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ivabradine
What this could lead to
If it works, this could point toward a treatment for long COVID symptoms such as dizziness and rapid heartbeat.
What could go wrong
This is a Phase 2 trial with only 181 participants, so results may not apply to everyone. The drug may not improve symptoms more than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • All sites listed under NCT06305780

    Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.